The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
Open accessAbstract
Purpose: Cetuximab, an antibody targeting the epidermal growth factor receptor (EGFR), is active in colorectal cancer (CRC). However, response rates range from only 10% to 20%. Here, we investigate hepatocyte growth factor (HGF)-dependent mesenchymal-epithelial transition factor (MET) activation as a mediator of cetuximab resistance through signal diversification in CRC cell lines. Experimental Design: DiFi, GEO, and LIM1215 cells were treated with varying concentrations and combinations of EGF, HGF, cetuximab, and PHA-665752 (a highly specific MET kinase inhibitor). Biological end points included proliferation, cell cycle arrest, and apoptosis. Proliferation was measured using WST-1 assays and synergy investigated via isobolograms. Expression and signaling were examined using immunoblotting. Results: EGFR and MET are coexpressed in these CRC cell lines, and dual receptor activation synergistically increased proliferation. Cetuximab inhibited cell growth by 60%–80% with an associated dephosphorylation of EGFR, MAPK, and/or AKT. Addition of HGF to cetuximab-treated cells phosphorylated MET, but not EGFR or ErbB3, restimulated the MAPK and AKT pathways, restored cell proliferation, and rescued cells from G1 arrest and apoptosis. Importantly, this effect could be abrogated by inhibiting MET activation with PHA-665752 or by downregulating MET expression with RNAi. Conclusions: HGF-induced MET activation is a novel mechanism of cetuximab resistance in CRC. Inhibition of the HGF-MET pathway may improve response to EGFR inhibitors in CRC, and combination therapy should be further investigated. Clin Cancer Res; 17(3); 472–82. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In these studies, only the simultaneous blockade of both MET and EGFR effectively impaired tumor growth in vivo.”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [103]
In the citing paper
“HGF-induced MET activation as a mechanism of attenuated sensitivity to cetuximab in CRC has been reported by preclinical studies using either CRC cell lines [103, 104] or, more recently, CRC spheroids enriched in cancer stem cells [105].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [103]
In the citing paper
“Moreover, the EGF ligands HGF and TGF-α can bind to MET and then increase the phosphorylation of MET and its downstream MAPK and AKT [121, 122].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“Mutations in BRAF, the serine protein recruited by KRAS, which occur in approximately 3%-10% of KRAS wild-type CRC cancer patients are associated with resistance to monoclonal antibodies targeting EGFR (18-20).”
Lièvre, A., Bachet, J., Boige, V., Cayre, A., Corre, D. L., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,485
Cited by
Sorted by citations
Items 101–176 of 176
Walk, E. L., & Weed, S. A. (2011) · Cancers · doi:10.3390/cancers3010747 · Cited by 25
Giampieri, R., Scartozzi, M., Prete, M. D., Maccaroni, E., Bittoni, A., Faloppi, L., Bianconi, M., Cecchini, L., & Cascinu, S. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.008 · Cited by 24
Khelwatty, S. A., Essapen, S., Seddon, A. M., Fan, Z., & Modjtahedi, H. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.319 · Cited by 24
HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
Shao, Z., Pan, H., Tu, S., Zhang, J., Yan, S., & Shao, A. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00801 · Cited by 24
Monteleone, F., Rosa, R., Vitale, M., DˈAmbrosio, C., Succoio, M., Formisano, L., Nappi, L., Romano, M. F., Scaloni, A., Tortora, G., et al. (2012) · PROTEOMICS · doi:10.1002/pmic.201200303 · Cited by 25
Beyond KRAS Status and Response to Anti-EGFR Therapy in Metastatic Colorectal Cancer
Perkins, G., Pilati, C., Blons, H., & Laurent-Puig, P. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.66 · Cited by 22
Takahashi, N., Iwasa, S., Taniguchi, H., Sasaki, Y., Shoji, H., Honma, Y., Takashima, A., Okita, N. T., Kato, K., Hamaguchi, T., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.74 · Cited by 22
Graves‐Deal, R., Bogatcheva, G. T., Rehman, S., Lu, Y., Higginbotham, J. N., & Singh, B. (2019) · Oncotarget · doi:10.18632/oncotarget.26663 · Cited by 22
Liu, J., Xie, L., Cheng, L., Qian, X., Liu, B., Hu, J. Y., Ren, W., & Yang, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s86966 · Cited by 21
Resistance to targeted cancer drugs through hepatocyte growth factor signaling
Heynen, G. J. J. E., Fonfara, A., & Bernards, R. (2014) · Cell Cycle · doi:10.4161/15384101.2014.988033 · Cited by 21
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer
Mardjuadi, F. I., Carrasco, J., Coche, J.-C., Sempoux, C. L., Jouret‐Mourin, A., Scalliet, P. G. M., Goeminne, J., Daisne, J., Delaunoit, T., Vuylsteke, P., et al. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0342-9 · Cited by 20
Pomerleau, V., Landry, M., Bernier, J., Vachon, P. H., & Saucier, C. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-240 · Cited by 19
Troiani, T., Napolitano, S., Martini, G., Martinelli, E., Cardone, C., Normanno, N., Vitagliano, D., Morgillo, F., Fenizia, F., Lambiase, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0211 · Cited by 18
Role of c-mesenchymal–epithelial transition pathway in gastric cancer
Fioroni, I., Dell’Aquila, E., Pantano, F., Intagliata, S., Caricato, M., Vincenzi, B., Coppola, R., Santini, D., & Tonini, G. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1037739 · Cited by 18
Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse
Chelakkot, C., Yang, H., & Shin, Y. K. (2022) · Pharmaceuticals · doi:10.3390/ph15010075 · Cited by 19
Chae, Y. K., Gagliato, D. D. M., Pai, S. G., Carneiro, B. A., Mohindra, N. A., Giles, F. J., Ramakrishnan-Geethakumari, P., Sohn, J., Liu, S., Chen, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152585 · Cited by 18
c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma.
Abou-Bakr, A. A.-E., & Elbasmi, A. (2013) · PubMed · Cited by 18
Mezquita, B., Pineda, E., Mezquita, J., Mezquita, P., Pau, M., Codony‐Servat, J., Martinez‐Balibrea, E., Mora, C., Maurel, J., & Mezquita, C. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22289 · Cited by 15
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy
Kasper, S., Reis, H., Ziegler, S., Nothdurft, S., Mueller, A. M., Goetz, M., Wiesweg, M., Phasue, J., Ting, S. C., Wieczorek, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17438 · Cited by 16
Genomic diversity of colorectal cancer: Changing landscape and emerging targets
Ahn, D. H., Ciombor, K. K., Mikhail, S., & Bekaii‐Saab, T. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i25.5668 · Cited by 14
Primary and acquired resistance to biologic therapies in gastrointestinal cancers
Lubner, S. J., Uboha, N. V., & Deming, D. A. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.16 · Cited by 14
Yang, H., Mo, C., Xun, Y., Liu, L. G., Li, W., Guan, J., Liu, J., Wu, J., Yang, A., Zheng, S., et al. (2019) · PubMed Central · Cited by 14
Yonesaka, K., Satoh, T., Ueda, S., Yoshida, T., Takeda, M., Shimizu, T., Okamoto, I., Nishio, K., Tamura, T., & Nakagawa, K. (2015) · PubMed · Cited by 13
Liu, D., Zhong, M., Zhan, D., Zhang, Y., & Liu, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7799 · Cited by 13
Pharmacological Targeting of Epithelial-to-Mesenchymal Transition in Colorectal Cancer
Zafari, N., Velayati, M., Nassiri, M., Khazaei, M., Hassanian, S. M., Ferns, G. A., & Avan, A. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220728152350 · Cited by 13
Emerging kinase inhibitors of the treatment of gastric cancer
Vincenzi, B., Imperatori, M., Silletta, M., Marrucci, E., Santini, D., & Tonini, G. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1051467 · Cited by 12
Pineda, E., Salud, A., Vila-Navarro, E., Safont, M., Llorente, B., Aparicio, J., Vera, R., Escudero, P., Casado, E., Bosch, C., et al. (2017) · Tumor Biology · doi:10.1177/1010428317705509 · Cited by 12
Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer
Owusu, B. Y., Vaid, M., Kaler, P., & Klampfer, L. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s25247 · Cited by 11
SOX8 promotes cetuximab resistance via HGF/MET bypass pathway activation in colorectal cancer
Piao, H., Qu, J., & Liu, Y.-P. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04378-z · Cited by 10
Predictive values of FAP and HGF for tumor angiogenesis and metastasis in colorectal cancer
H., T., Gao, C., Xie, R., Yang, X.-Y., Dai, W., Zhang, J., Yan, W., & Wu, S. N. (2017) · Neoplasma · doi:10.4149/neo_2017_609 · Cited by 10
Wen, D., Wang, Y., Zhu, Z., Huang, Z., Cui, L., Wu, T., & Liu, C. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165923 · Cited by 11
Kim, S., Park, H., Kim, K., Kim, J., Sung, J. H., Nam, M., Lee, J. H., Jung, E. H., Suh, K. J., Lee, J. Y., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03872-4 · Cited by 10
Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer
Song, N., Qu, X., Liu, S., Zhang, S., Liu, J., Qu, J., Zheng, H., Liu, Y., & Che, X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4692 · Cited by 10
Correlation of c-MET expression with clinical characteristics and the prognosis of colorectal cancer
Lai, X., Dong, Q., Xu, F., Wu, S.-P., Yang, D., Liu, C., Li, Y., Li, Z., & Ma, D. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-536 · Cited by 9
Napolitano, S., Martini, G., Martinelli, E., Corte, C. M. D., Morgillo, F., Belli, V., Cardone, C., Matrone, N., Ciardiello, F., & Troiani, T. (2017) · Oncotarget · doi:10.18632/oncotarget.19797 · Cited by 9
Iwasaki, M., Zhao, H., Hu, C., Saito, J., Wu, L., Sherwin, A., Ishikawa, M., Sakamoto, A., Buggy, D. J., & Ma, D. (2022) · Cell Biology and Toxicology · doi:10.1007/s10565-022-09747-9 · Cited by 9
Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth
Wong, J. S., Warbrick, E., Vojtesek, B., Hill, J., & Lane, D. P. (2013) · Oncotarget · doi:10.18632/oncotarget.1075 · Cited by 9
p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks
Axelrod, M. J., Gordon, V. L., Mendez, R. E., Leimgruber, S., Conaway, M. R., Sharlow, E. R., Jameson, M. J., Gioeli, D. G., & Weber, M. J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.03.013 · Cited by 10
LI, J., Liu, Y., XU, J.-H., XU, Z.-P., Zheng, S. S., & Ding, K. (2015) · Oncology Letters · doi:10.3892/ol.2015.3964 · Cited by 9
Nanomedicine in HNSCC therapy-a challenge to conventional therapy
Li, C., Fang, Y., Xu, S., Zhao, J., Dong, D., & Li, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1434994 · Cited by 9
Role of the MET–HGF axis in colorectal cancer: precepts and prospects
Raghav, K. P. S., & Eng, C. (2012) · Colorectal Cancer · doi:10.2217/crc.12.40 · Cited by 8
Zhang, J., Xiang, S., Liu, D., Pei, X.-M., Chen, M., Zhao, Y., Wang, Y., Wang, Q., Kang, L., Yu, Z., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07818-3 · Cited by 6
EGFR (ErbB) Signaling Pathways in Pancreatic Cancer Pathogenesis
Williams, M., Lomberk, G. A., & Urrutia, R. A. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_15 · Cited by 6
Wang, Z. P., He, C., Liu, L., Ma, N., Chen, X., Zheng, D., & Qiu, G. (2017) · Neoplasma · doi:10.4149/neo_2017_308 · Cited by 5
Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4
Isothiocyanatostilbenes as novel c-Met inhibitors
Gray, A. L., Coleman, D. T., Castore, R., Mohyeldin, M. M., Sayed, K. A. E., & Cardelli, J. A. (2015) · Oncotarget · doi:10.18632/oncotarget.5748 · Cited by 3
Bianchi, A. S., & Siena, S. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_19 · Cited by 3
Ye, P., Yang, X., Wang, H., Ren, Y., Gao, M., Wang, Y., Guo, Y., Sun, Y., & Xu, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148141 · Cited by 2
Why Cetuximab is Not Active in the Adjuvant Setting
Murray, J. C., Wu, C. S.-Y., & Weiner, L. M. (2011) · Current Colorectal Cancer Reports · doi:10.1007/s11888-011-0103-4 · Cited by 2
EGFR (ErbB) Signaling Pathways in Pancreatic Cancer Pathogenesis
Williams, M., Lomberk, G. A., & Urrutia, R. A. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_15-2 · Cited by 2
Innovative Therapeutic Strategies Targeting Colorectal Cancer Stem Cells
Giammona, A., Mangiapane, L. R., Franco, S. D., Benfante, A., Todaro, M., & Stassi, G. (2017) · Current Colorectal Cancer Reports · doi:10.1007/s11888-017-0353-x · Cited by 2
Klinghammer, K. F., Keller, J. C., George, J. R., Hoffmann, J., Chan, E. K. L., & Hayman, M. J. (2017) · International Journal of Cancer · doi:10.1002/ijc.31045 · Cited by 2
Resistance of Colorectal Tumors to Anti-EGFR Antibodies
Trusolino, L., & Leto, S. M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_1 · Cited by 2
Liu, L., 陈颖君, Guo, M., Yun, F., Li, X., Chen, L., Li, Y. M., & Li, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782130 · Cited by 1
Tao, H., Shen, M., Zhang, X., Wang, M., Wu, Y., Sun, H., Chen, L., Yang, Y., Chen, K., & Li, D. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-1237 · Cited by 1
Kermorgant, S. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00460 · Cited by 1
Vladimirova, L. Y., Льянова, А. А., Frantsiyants, E. M., Kutilin, D. S., & Engibaryan, M. A. (2019) · Malignant tumours · doi:10.18027/2224-5057-2018-8-4-13-25 · Cited by 1
Graham, T. A. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736145192.793584899 · Cited by 1
Mechanisms of resistance to EGFR inhibitors in colorectal cancers
Dhillon, T. (2014) · Colorectal Cancer · doi:10.2217/crc.14.37
Pharmacology and Clinical Development of New Molecularly Targeted Agents
Giovannetti, E., & Galvani, E. (2015) · Current clinical pathology · doi:10.1007/978-1-4939-2047-1_3
Balancing selectivity and efficacy of bispecific antibodies
Sellmann, C. (2016) · New Biotechnology · doi:10.1016/j.nbt.2016.06.927
Drug Resistance and Drug Synergism
Silverman, R. B., Xue, F., & Juncosa, J. I. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-382030-3.00007-6
Head and Neck Cancer Invasion: Contributions of Actin Regulatory Proteins and the Microenvironment
Walk, E. L. (2014) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6887
Stroma and vessel characteristics in cancer : impact on prognosis and response to treatment
Mezheyeuski, A. (2016) · Figshare
resistance to EGFR blockade in colorectal cancer cells
Hobor, S., Emburgh, B. O. V., Crowley, E. H., Misale, S., Nicolantonio, F. D., & Bardelli, A. (2014)
Ren, K., Gong, H., Ma, Z., Tian, L., Ye, W., Lv, X., & Wu, C. (2021) · Drug Development Research · doi:10.1002/ddr.21894
Use of MET kinase inhibitors to overcome cetuximab resistance in colorectal cancer
Ma, Z., Fu, W., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00019-5
Data from InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Ma, Y., Tang, N., Thompson, R. C., Mobley, B. C., Clark, S. W., Sarkaria, J. N., & Wang, J. (2023) · doi:10.1158/1078-0432.c.6524027.v1
Novel targeting strategies on signaling pathways of colorectal cancer
Sabale, P., Waghmare, S., Potey, L., Khedekar, P. B., Sabale, V., Rarokar, N. R., Chikhale, R. V., & Palekar, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13870-6.00017-9
Zhang, S., Zhao, A., Li, S., Hao, X., & Liu, M. (2025) · Research Square · doi:10.21203/rs.3.rs-8247185/v1
Macrophage-Related Interaction Pathways in Tumor Stroma
Gusenbauer, S. (2012) · mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich)
Banerjee, S., Elmeligy, A., Awanis, G., Cicovacki, N., Scalcione, J., McColl, J. T., Lézé, B., Bidula, S. M., Gavrilović, J., Warren, D. T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.23.701283
Deciphering the colorectal tumor microenvironment: Interactions and targets for effective therapy
Zhao, J., Shi, C., Du, Y., Li, G., & Yan, C. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118303
Forti, S. F., & Forti, F. L. (2026) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases4030021
Ying, Z., Xiaoli, W., Liu, X., Shen, C., Shen, D., & Ge, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1936498
Metadata
- Authors
- Liska, D., Chen, C.-T., Bachleitner-Hofmann, T., Christensen, J. G., & Weiser, M. R.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Authors' Affiliations: 1Departments of Surgery, Memorial Sloan-Kettering Cancer Center, New York; 2Department of Cancer Research, Pfizer Global Research and Development, La Jolla Laboratories, La Jolla, California
- Corresponding author
- Weiser, Martin R.
- Venue
- Clinical Cancer Research
- Published
- 2011-02-01
- Volume
- 17
- Issue
- 3
- Pages
- 472-482
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3033451
- OpenAlex
- W2133129337
- Cited by
- 176
- References
- 54
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 9 · 2020: 9 · 2019: 7 · 2018: 6 · 2017: 23 · 2016: 17 · 2015: 22 · 2014: 23 · 2013: 18 · 2012: 11
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (T32CA009501)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- hepatocyte growth factor, MET activation, cetuximab resistance, EGFR inhibition, colorectal cancer, mesenchymal-epithelial transition, PHA-665752, MAPK signaling, Akt signaling, cell proliferation, apoptosis, G1 cell cycle arrest, combination therapy
- MeSH terms
- Cetuximab, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Colorectal Neoplasms, Signal Transduction, Transcriptional Activation, Hepatocyte Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Cell Line, Tumor, Cell Proliferation, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
